» Articles » PMID: 35398305

Erodible Thermogelling Hydrogels for Localized Mitochondrial Transplantation to the Spinal Cord

Abstract

We developed a thermal-gelling, erodible hydrogel system for localized delivery of viable mitochondria in vivo, as well as labeled transplanted mitochondria with specific dyes and/or genetically modified mitochondria tagged with red fluorescence protein (RFP). We also employed cell lines to optimize a hydrogel composed of methylcellulose and hyaluronic acid designed to preserve bioenergetics while facilitating mitochondrial release. We further investigated how transplantation of allogeneic or xenogeneic mitochondria into respective cell lines affects host cellular metabolism, as measured by MTS assay. We found that 70% of mitochondria are released from the hydrogel within 20 min at 37 °C, that the respiratory capacity of hydrogel-released mitochondria over 60 min was greater than those without gel, and that MTR-labeling of mitochondria is not indelible. RFP-tagged transgenic mitochondria isolated from modified SH-SY5Y human neuroblastoma cells showed effective uptake into both naïve SH-SY5Y cells and rat PC-12 cells, notably when released from hydrogel. The hydrogel both protected the mitochondria at physiological conditions in vitro while solidifying and diffusing within 60 min locally in situ. To assess metabolic effects, both cell lines were transplanted with different concentrations of SH-SY5Y or PC-12 cell line-derived mitochondria and all resulted in significant increases in metabolism at 6- and 24-hour after transplantation. Alternatively, transplanted mitochondria at highest concentration from rat brain and spinal cord tissues reduced metabolic activities after 24-hour. Along with hydrogel refinements, we are further investigating whether such metabolic changes are due to alterations in cell proliferation or the number of exogenous mitochondria incorporated into individual host cells.

Citing Articles

Mechanism and prospects of mitochondrial transplantation for spinal cord injury treatment.

Wang Q, Wang X, Shang Z, Zhao L Stem Cell Res Ther. 2024; 15(1):457.

PMID: 39609871 PMC: 11606159. DOI: 10.1186/s13287-024-04077-5.


Advances and Challenges in Immune-Modulatory Biomaterials for Wound Healing Applications.

Cao Y, Sun J, Qin S, Zhou Z, Xu Y, Liu C Pharmaceutics. 2024; 16(8).

PMID: 39204335 PMC: 11360739. DOI: 10.3390/pharmaceutics16080990.


Metabolic reprogramming: a new option for the treatment of spinal cord injury.

Chen J, Chen J, Yu C, Xia K, Yang B, Wang R Neural Regen Res. 2024; 20(4):1042-1057.

PMID: 38989936 PMC: 11438339. DOI: 10.4103/NRR.NRR-D-23-01604.


Bridging the gap between in vitro and in vivo models: a way forward to clinical translation of mitochondrial transplantation in acute disease states.

Bodenstein D, Siebiger G, Zhao Y, Clasky A, Mukkala A, Beroncal E Stem Cell Res Ther. 2024; 15(1):157.

PMID: 38816774 PMC: 11140916. DOI: 10.1186/s13287-024-03771-8.


Skeletal muscle dysfunction in amyotrophic lateral sclerosis: a mitochondrial perspective and therapeutic approaches.

Kubat G, Picone P Neurol Sci. 2024; 45(9):4121-4131.

PMID: 38676818 PMC: 11306305. DOI: 10.1007/s10072-024-07508-6.


References
1.
Moskowitzova K, Orfany A, Liu K, Ramirez-Barbieri G, Thedsanamoorthy J, Yao R . Mitochondrial transplantation enhances murine lung viability and recovery after ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2019; 318(1):L78-L88. PMC: 6985877. DOI: 10.1152/ajplung.00221.2019. View

2.
Puleston D . Detection of Mitochondrial Mass, Damage, and Reactive Oxygen Species by Flow Cytometry. Cold Spring Harb Protoc. 2015; 2015(9):pdb.prot086298. DOI: 10.1101/pdb.prot086298. View

3.
Bazley F, Pashai N, Kerr C, All A . The effects of local and general hypothermia on temperature profiles of the central nervous system following spinal cord injury in rats. Ther Hypothermia Temp Manag. 2014; 4(3):115-24. PMC: 4151073. DOI: 10.1089/ther.2014.0002. View

4.
Emani S, McCully J . Mitochondrial transplantation: applications for pediatric patients with congenital heart disease. Transl Pediatr. 2018; 7(2):169-175. PMC: 5938257. DOI: 10.21037/tp.2018.02.02. View

5.
Patel S, Sullivan P, Pandya J, Rabchevsky A . Differential effects of the mitochondrial uncoupling agent, 2,4-dinitrophenol, or the nitroxide antioxidant, Tempol, on synaptic or nonsynaptic mitochondria after spinal cord injury. J Neurosci Res. 2008; 87(1):130-140. PMC: 5291118. DOI: 10.1002/jnr.21814. View